Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1

Sagar Ghosh, Fei Gu, Chou Miin Wang, Chun Lin Lin, Joseph Liu, Howard T Wang, Peter Ravdin, Yanfen Hu, Hui-ming Huang, Rong Li

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Early pregnancy in women by the age of 20 is known to have a profound effect on reduction of lifelong breast cancer risk as compared to their nulliparous counterparts. Additional pregnancies further enhance the protection against breast cancer development. Nationwide trend of delayed pregnancy may contribute to the recently reported increase in the incidence of advanced breast cancer among young women in this country. The underlying mechanism for the parity-associated reduction of breast cancer risk is not clearly understood. The purpose of the current study is to use whole-genome DNA methylation profiling to explore a potential association between parity and epigenetic changes in breast tissue from women with early parity and nulliparity. Breast tissue was collected from age-matched cancer-free women with early parity (age < 20; n = 15) or nulliparity (n = 13). The methyl-CpG binding domain-based capture-sequencing technology was used for whole-genome DNA methylation profiling. Potential parity-associated hypermethylated genes were further verified by locus-specific pyrosequencing, using an expanded cohort of parous (n = 19) and nulliparous (n = 16) women that included the initial samples used in the global analysis. Our study identified six genes that are hypermethylated in the parous group (P < 0.05). Pyrosequencing confirmed parity-associated hypermethylation at multiple CpG islands of the FOXA1 gene, which encodes a pioneer factor that facilitates chromatin binding of estrogen receptor α. Our work identifies several potential methylation biomarkers for parity-associated breast cancer risk assessment. In addition, the results are consistent with the notion that parity-associated epigenetic silencing of FOXA1 contributes to long-term attenuation of the estrogenic impact on breast cancer development.

Original languageEnglish (US)
Pages (from-to)653-659
Number of pages7
JournalBreast Cancer Research and Treatment
Volume147
Issue number3
DOIs
StatePublished - Sep 24 2014

Fingerprint

DNA Fingerprinting
DNA Methylation
Parity
Genome
Breast Neoplasms
Epigenomics
Pregnancy
Breast
Genes
CpG Islands
Estrogen Receptors
Methylation
Chromatin
Biomarkers
Technology

Keywords

  • Breast cancer risk reduction
  • DNA methylation
  • FOXA1
  • Parity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1. / Ghosh, Sagar; Gu, Fei; Wang, Chou Miin; Lin, Chun Lin; Liu, Joseph; Wang, Howard T; Ravdin, Peter; Hu, Yanfen; Huang, Hui-ming; Li, Rong.

In: Breast Cancer Research and Treatment, Vol. 147, No. 3, 24.09.2014, p. 653-659.

Research output: Contribution to journalArticle

Ghosh, Sagar ; Gu, Fei ; Wang, Chou Miin ; Lin, Chun Lin ; Liu, Joseph ; Wang, Howard T ; Ravdin, Peter ; Hu, Yanfen ; Huang, Hui-ming ; Li, Rong. / Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1. In: Breast Cancer Research and Treatment. 2014 ; Vol. 147, No. 3. pp. 653-659.
@article{768762406a104488b7465930e0f401f5,
title = "Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1",
abstract = "Early pregnancy in women by the age of 20 is known to have a profound effect on reduction of lifelong breast cancer risk as compared to their nulliparous counterparts. Additional pregnancies further enhance the protection against breast cancer development. Nationwide trend of delayed pregnancy may contribute to the recently reported increase in the incidence of advanced breast cancer among young women in this country. The underlying mechanism for the parity-associated reduction of breast cancer risk is not clearly understood. The purpose of the current study is to use whole-genome DNA methylation profiling to explore a potential association between parity and epigenetic changes in breast tissue from women with early parity and nulliparity. Breast tissue was collected from age-matched cancer-free women with early parity (age < 20; n = 15) or nulliparity (n = 13). The methyl-CpG binding domain-based capture-sequencing technology was used for whole-genome DNA methylation profiling. Potential parity-associated hypermethylated genes were further verified by locus-specific pyrosequencing, using an expanded cohort of parous (n = 19) and nulliparous (n = 16) women that included the initial samples used in the global analysis. Our study identified six genes that are hypermethylated in the parous group (P < 0.05). Pyrosequencing confirmed parity-associated hypermethylation at multiple CpG islands of the FOXA1 gene, which encodes a pioneer factor that facilitates chromatin binding of estrogen receptor α. Our work identifies several potential methylation biomarkers for parity-associated breast cancer risk assessment. In addition, the results are consistent with the notion that parity-associated epigenetic silencing of FOXA1 contributes to long-term attenuation of the estrogenic impact on breast cancer development.",
keywords = "Breast cancer risk reduction, DNA methylation, FOXA1, Parity",
author = "Sagar Ghosh and Fei Gu and Wang, {Chou Miin} and Lin, {Chun Lin} and Joseph Liu and Wang, {Howard T} and Peter Ravdin and Yanfen Hu and Hui-ming Huang and Rong Li",
year = "2014",
month = "9",
day = "24",
doi = "10.1007/s10549-014-3132-2",
language = "English (US)",
volume = "147",
pages = "653--659",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1

AU - Ghosh, Sagar

AU - Gu, Fei

AU - Wang, Chou Miin

AU - Lin, Chun Lin

AU - Liu, Joseph

AU - Wang, Howard T

AU - Ravdin, Peter

AU - Hu, Yanfen

AU - Huang, Hui-ming

AU - Li, Rong

PY - 2014/9/24

Y1 - 2014/9/24

N2 - Early pregnancy in women by the age of 20 is known to have a profound effect on reduction of lifelong breast cancer risk as compared to their nulliparous counterparts. Additional pregnancies further enhance the protection against breast cancer development. Nationwide trend of delayed pregnancy may contribute to the recently reported increase in the incidence of advanced breast cancer among young women in this country. The underlying mechanism for the parity-associated reduction of breast cancer risk is not clearly understood. The purpose of the current study is to use whole-genome DNA methylation profiling to explore a potential association between parity and epigenetic changes in breast tissue from women with early parity and nulliparity. Breast tissue was collected from age-matched cancer-free women with early parity (age < 20; n = 15) or nulliparity (n = 13). The methyl-CpG binding domain-based capture-sequencing technology was used for whole-genome DNA methylation profiling. Potential parity-associated hypermethylated genes were further verified by locus-specific pyrosequencing, using an expanded cohort of parous (n = 19) and nulliparous (n = 16) women that included the initial samples used in the global analysis. Our study identified six genes that are hypermethylated in the parous group (P < 0.05). Pyrosequencing confirmed parity-associated hypermethylation at multiple CpG islands of the FOXA1 gene, which encodes a pioneer factor that facilitates chromatin binding of estrogen receptor α. Our work identifies several potential methylation biomarkers for parity-associated breast cancer risk assessment. In addition, the results are consistent with the notion that parity-associated epigenetic silencing of FOXA1 contributes to long-term attenuation of the estrogenic impact on breast cancer development.

AB - Early pregnancy in women by the age of 20 is known to have a profound effect on reduction of lifelong breast cancer risk as compared to their nulliparous counterparts. Additional pregnancies further enhance the protection against breast cancer development. Nationwide trend of delayed pregnancy may contribute to the recently reported increase in the incidence of advanced breast cancer among young women in this country. The underlying mechanism for the parity-associated reduction of breast cancer risk is not clearly understood. The purpose of the current study is to use whole-genome DNA methylation profiling to explore a potential association between parity and epigenetic changes in breast tissue from women with early parity and nulliparity. Breast tissue was collected from age-matched cancer-free women with early parity (age < 20; n = 15) or nulliparity (n = 13). The methyl-CpG binding domain-based capture-sequencing technology was used for whole-genome DNA methylation profiling. Potential parity-associated hypermethylated genes were further verified by locus-specific pyrosequencing, using an expanded cohort of parous (n = 19) and nulliparous (n = 16) women that included the initial samples used in the global analysis. Our study identified six genes that are hypermethylated in the parous group (P < 0.05). Pyrosequencing confirmed parity-associated hypermethylation at multiple CpG islands of the FOXA1 gene, which encodes a pioneer factor that facilitates chromatin binding of estrogen receptor α. Our work identifies several potential methylation biomarkers for parity-associated breast cancer risk assessment. In addition, the results are consistent with the notion that parity-associated epigenetic silencing of FOXA1 contributes to long-term attenuation of the estrogenic impact on breast cancer development.

KW - Breast cancer risk reduction

KW - DNA methylation

KW - FOXA1

KW - Parity

UR - http://www.scopus.com/inward/record.url?scp=84918835649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918835649&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3132-2

DO - 10.1007/s10549-014-3132-2

M3 - Article

C2 - 25234841

AN - SCOPUS:84918835649

VL - 147

SP - 653

EP - 659

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -